Open Access. Powered by Scholars. Published by Universities.®
Social and Behavioral Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Social and Behavioral Sciences
The Influence Of Hla Supertype On Thymidine Analogue Associated With Low Peripheral Fat In Hiv, Damien Cordery, Allison Martin, Janaki Amin, Anthony Kelleher, Sean Emery, David Cooper
The Influence Of Hla Supertype On Thymidine Analogue Associated With Low Peripheral Fat In Hiv, Damien Cordery, Allison Martin, Janaki Amin, Anthony Kelleher, Sean Emery, David Cooper
Allison Humphries Dr
Objectives: To examine the relationship between human leukocyte antigen (HLA) genotype and body composition changes induced by thymidine analogue nucleoside reverse transcriptase inhibitor (NtRTI) use in HIV-positive individuals. Design: Data collected during the Simplification with Tenofovir-Emtricitabine (TDF-FTC) or Abacavir-Lamivudine (ABC-3TC) (STEAL) study were analysed to examine the potential association of HLA genotypes with changes in body composition in treatment-experienced HIV-positive individuals. Methods: Demographic, HIV-related, body composition and HLA genotyping data from the STEAL study were used in this analysis. The mean percentage peripheral fat at study baseline was compared in participants with and without prior NtRTI use. Analyses …
Ritonavir-Boosted Lopinavir Plus Nucleoside Or Nucleotide Reverse Transcriptase Inhibitors Versus Ritonavir-Boosted Lopinavir Plus Raltegravir For Treatment Of Hiv-1 Infection In Adults With Virological Failure Of A Standard First-Line Art Regimen (Second-Line): A Randomised, Open-Label, Non-Inferiority Study, Mark Boyd, N Kumarasamy, Cecilia Moore, C Nwizu, M Losso, L Mohapi, Allison Martin, S Kerr, A Sohn, H Teppler, O Van De Steen, J-M Molina, Sean Emery, David Cooper
Ritonavir-Boosted Lopinavir Plus Nucleoside Or Nucleotide Reverse Transcriptase Inhibitors Versus Ritonavir-Boosted Lopinavir Plus Raltegravir For Treatment Of Hiv-1 Infection In Adults With Virological Failure Of A Standard First-Line Art Regimen (Second-Line): A Randomised, Open-Label, Non-Inferiority Study, Mark Boyd, N Kumarasamy, Cecilia Moore, C Nwizu, M Losso, L Mohapi, Allison Martin, S Kerr, A Sohn, H Teppler, O Van De Steen, J-M Molina, Sean Emery, David Cooper
Allison Humphries Dr
Background Uncertainty exists about the best treatment for people with HIV-1 who have virological failure with first-line combination antiretroviral therapy of a non-nucleoside analogue (NNRTI) plus two nucleoside or nucleotide analogue reverse transcriptase inhibitors (NtRTI). We compared a second-line regimen combining two new classes of drug with a WHO-recommended regimen. Methods We did this 96-week, phase 3b/4, randomised, open-label non-inferiority trial at 37 sites worldwide. Adults with HIV-1 who had confirmed virological failure (plasma viral load >500 copies per mL) after 24 weeks or more of first-line treatment were randomly assigned (1:1) to receive ritonavir-boosted lopinavir plus two or three …
Abacavir Does Not Affect Circulating Levels Of Inflammatory Or Coagulopathic Biomarkers In Suppressed Hiv: A Randomized Clinical Trial, Allison Martin, Janaki Amin, David Cooper, Andrew Carr, Anthony Kelleher, Mark Bloch, David Baker, Ian Woolley, Sean Emery
Abacavir Does Not Affect Circulating Levels Of Inflammatory Or Coagulopathic Biomarkers In Suppressed Hiv: A Randomized Clinical Trial, Allison Martin, Janaki Amin, David Cooper, Andrew Carr, Anthony Kelleher, Mark Bloch, David Baker, Ian Woolley, Sean Emery
Allison Humphries Dr
Objective: The Simplification of antiretroviral therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine trial (STEAL) study randomized HIV participants to switch existing nucleoside reverse transcriptase inhibitors (NRTI) to either abacavir/lamivudine (ABC/3TC; n = 179) or tenofovir/emtricitabine (TDF/FTC; n = 178). An increased risk in cardiovascular disease (CVD) was reported (hazard ratio 7.7, P = 0.048) in ABC/3TC recipients compared with TDF/FTC in the STEAL study. The impact of ABC/3TC treatment on a range of CVD and inflammatory biomarkers was explored. Design and methods: Biomarkers were assessed at 0, 12, 24, and 48 weeks to examine: inflammation - high sensitive C-reactive protein, amyloid-P, amyloid-A, …